Views & Analysis Do research with us, not on us More needs to be done to ensure patient centricity is at the heart of all clinical trials.
Views & Analysis Patient-centricity and pharma: where are we now? How should the industry define patient-centricity, and how should progress be measured?
Views & Analysis Rethinking rare diseases: treat the whole patient CRDN wants to break down barriers in communication between rare disease patients, HCPs and industry.
Debates & Insight Sponsored Patient centricity: Identifying how Boehringer Ingelheim UK ... Boehringer Ingelheim UK provides an update on its patient centricity initiative ahead of a new white paper later this year.
Views & Analysis Clinical trial lay summaries: a clearer picture emerges EC wants pharma to make clinical trial results more patient-friendly.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.